Diabetes und Impfen

Menschen mit Diabetes mellitus haben ein krankheitsimmanent erhöhtes Infektionsrisiko. Impfungen stellen eine der wirksamsten und wichtigsten medizinischen Maßnahmen zur Prävention von Infektionen dar. Dieser Beitrag soll einen Überblick über die aktuellen Impfempfehlungen speziell für Menschen mit Diabetes mellitus geben.

Abstract

Diabetes affects T cell and B cell function, causing an increased risk for viral, bacterial, and fungal infections. Education of patients with diabetes, along with optimal glycaemic control, can minimize the risk of life-threatening infections. To this end it is of upmost importance that patients with diabetes receive all publicly recommended vaccinations in a timely fashion. The German Standing Committee on Vaccination (STIKO) (Ständige Impfkommission beim Robert Koch-Institut, Berlin) publishes every year recommendations concerning vaccinations for the general population as well as specific recommendations for individuals with chronic diseases, such as diabetes mellitus.

Schlüsselwörter

Diabetes mellitus - Infektionsrisiko - Impfung

Key words

diabetes mellitus - infectious risk - vaccination

Publication History

Article published online:
02 June 2021

• Literatur

• 1 Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab 2012; 16 (Suppl. 01) S27-S36 DOI: 10.4103/2230-8210.94253.
• 2 Critchley JA, Carey IM, Harris T. et al Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study. Diabetes Care 2018; 41: 2127-2135 DOI: 10.2337/dc18-0287.
• 3 Carey IM, Critchley JA, DeWilde S. et al Risk of infection in type 1 and type 2 diabetes compared with the general population: a matched cohort study. Diabetes Care 2018; 41: 513-521 DOI: 10.2337/dc17-2131.
• 4 Robert Koch-Institut. Empfehlungen der Ständigen Impfkommission beim Robert Koch-Institut. 2020/2021. Im Internet (Stand: 29.03.2021): http://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/Impfempfehlungen_node.html
• 5 Pletz MW, Ewig S, Heppner HJ. et al [Position Paper on Adult Pneumococcal Vaccination: Position Paper of the German Respiratory Society and the German Geriatric Society]. Pneumologie 2015; 69: 633-637 DOI: 10.1055/s-0034-1393413.
• 6 Pletz MW, von Baum H, van der Linden M. et al The burden of pneumococcal pneumonia – experience of the German competence network CAPNETZ. Pneumologie 2012; 66: 470-475 DOI: 10.1055/s-0032-1310103.
• 7 Torres A, Blasi F, Dartois N. et al Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax 2015; 70: 984-989 DOI: 10.1136/thoraxjnl-2015-206780.
• 8 Robert Koch-Institut. Wissenschaftliche Begründung für die Aktualisierung der Empfehlung zur Indikationsimpfung gegen Pneumokokken für Risikogruppen. Epid Bull 2016; 37: 385-406
• 9 Broker M, Berti F, Schneider J. et al Polysaccharide conjugate vaccine protein carriers as a “neglected valency” – Potential and limitations. Vaccine 2017; 35: 3286-3294 DOI: 10.1016/j.vaccine.2017.04.078.
• 10 Robert Koch-Institut. Wissenschaftliche Begründung für die Aktualisierung der Pneumokokken-Impfempfehlung für Senioren. Epid Bull 2016; 36: 352-381
• 11 Caya CA, Boikos C, Desai S. et al Dosing regimen of the 23-valent pneumococcal vaccination: a systematic review. Vaccine 2015; 33: 1302-1312 DOI: 10.1016/j.vaccine.2015.01.060.
• 12 Huijts SM, van Werkhoven CH, Bolkenbaas M. et al Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly. Vaccine 2017; 35: 4444-4449 DOI: 10.1016/j.vaccine.2017.01.071.
• 13 Pendharkar SA, Mathew J, Petrov MS. Age- and sex-specific prevalence of diabetes associated with diseases of the exocrine pancreas: A population-based study. Dig Liver Dis 2017; 49: 540-544 DOI: 10.1016/j.dld.2016.12.010.
• 14 Ganatra RB, McKenna JJ, Bramley AM. et al Adults with diabetes hospitalized with pandemic influenza A(H1N1)pdm09--U.S. 2009. Diabetes Care 2013; 36: e94 DOI: 10.2337/dc13-0005.
• 15 Sheridan PA, Paich HA, Handy J. et al The antibody response to influenza vaccination is not impaired in type 2 diabetics. Vaccine 2015; 33: 3306-3313 DOI: 10.1016/j.vaccine.2015.05.043.
• 16 Jimenez-Garcia R, Lopez-de-Andres A, Hernandez-Barrera V. et al Influenza vaccination in people with type 2 diabetes, coverage, predictors of uptake, and perceptions. Result of the MADIABETES cohort a 7years follow up study. Vaccine 2017; 35: 101-108 DOI: 10.1016/j.vaccine.2016.11.039.
• 17 Forbes HJ, Bhaskaran K, Thomas SL. et al Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: A cohort study. Neurology 2016; 87: 94-102 DOI: 10.1212/WNL.0000000000002808.
• 18 Saadatian-Elahi M, Bauduceau B, Del-Signore C. et al Diabetes as a risk factor for herpes zoster in adults: A synthetic literature review. Diabetes Res Clin Pract 2020; 159: 107983 DOI: 10.1016/j.diabres.2019.107983.
• 19 Lal H, Cunningham AL, Godeaux O. et al Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372: 2087-2096 DOI: 10.1056/NEJMoa1501184.
• 20 Cunningham AL, Lal H, Kovac M. et al Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016; 375: 1019-1032 DOI: 10.1056/NEJMoa1603800.
• 21 Schwarz TF, Volpe S, Catteau G. et al Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccin Immunother 2018; 14: 1370-1377 DOI: 10.1080/21645515.2018.1442162.
• 22 Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol 2020; 92: 401-402 DOI: 10.1002/jmv.25678.
• 23 Hui DS, Azhar EI, Madani TA. et al The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health – The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 2020; 91: 264-266 DOI: 10.1016/j.ijid.2020.01.009.
• 24 World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19–20 March 2020. Im Internet (Stand: 29.03.2021): http://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---20-march-2020
• 25 World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Im Internet (Stand: 29.03.2021): http://covid19.who.int/
• 26 Zhu N, Zhang D, Wang W. et al A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727-733 DOI: 10.1056/NEJMoa2001017.
• 27 Centers for Disease Control and Prevention. How COVID-19 Spreads. Updated Oct. 28, 2020. Im Internet (Stand: 29.03.2021): http://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html
• 28 Guan WJ, Ni ZY, Hu Y. et al Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708-1720 DOI: 10.1056/NEJMoa2002032.
• 29 Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol 2020; 101: 791-797 DOI: 10.1099/jgv.0.001439.
• 30 Schilling J, Lehfeld A, Schumacher D. et al RKI COVID-19 Study Group. Krankheitsschwere der ersten COVID-19-Welle in Deutschland basierend auf den Meldungen gemäß Infektionsschutzgesetz. Journal of Health Monitoring 2020; 5 (Suppl. 11) 1-20
• 31 Dong Y, Mo X, Hu Y. et al Epidemiology of COVID-19 among children in China. Pediatrics 2020; 145: e20200702 DOI: 10.1542/peds.2020-0702.
• 32 Richardson S, Hirsch JS, Narasimhan M. et al Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA 2020; 323: 2052-2059 DOI: 10.1001/jama.2020.6775.
• 33 Cariou B, Hadjadj S, Wargny M. et al Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 2020; 63: 1500-1515 DOI: 10.1007/s00125-020-05180-x.
• 34 Vygen-Bonnet S, Koch J, Bogdan C. et al Beschluss der STIKO zur 1. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung. Epid Bull 2021; 2: 3-71 DOI: 10.25646/7820.2.
• 35 Lurie N, Saville M, Hatchett R. et al Developing Covid-19 vaccines at pandemic speed. N Engl J Med 2020; 382: 1969-1973 DOI: 10.1056/NEJMp2005630.
• 36 Polack FP, Thomas SJ, Kitchin N. et al Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383: 2603-2615 DOI: 10.1056/NEJMoa2034577.
• 37 Voysey M, Clemens SAC, Madhi SA. et al Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397: 99-111 DOI: 10.1016/S0140-6736(20)32661-1.
• 38 Greinacher A, Thiele T, Warkentin TE. et al Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 vaccination. published online on April 9, 2021, at NEJM.org. DOI: 10.1056/NEJMoa2104840 .